Evidence grows for value of high-field MRI in prostate cancer Rx strategy

Publication
Article
OncologyONCOLOGY Vol 18 No 4
Volume 18
Issue 4

VIENNA-Image-guided intensity-modulated radiotherapy, high-intensity focused ultrasound, and cryotherapy are increasing the curative treatment options for men with prostate cancer. The problem is how to determine which patients are most suitable for these therapies.

ABSTRACT: New treatments for prostate cancer require precise localization of disease, but how to determine which patients are most suitable for these therapies? High-field MRI could be the answe

VIENNA-Image-guided intensity-modulated radiotherapy, high-intensity focused ultrasound, and cryotherapy are increasing the curative treatment options for men with prostate cancer. The problem is how to determine which patients are most suitable for these therapies.

The new treatments for prostate cancer require precise localization of disease, but routinely used imaging techniques are not sensitive or specific enough for accurate staging. Gray-scale transrectal ultrasound has a sensitivity of 30% to 50% and specificity of 77% to 90% for local staging and tumor localization, and 1.5T MRI has a joint sensitivity and specificity of 71% to 74% for conventional anatomical prostate imaging, according to recent research.

High-field MRI could be the answer, according to a special focus session at the European Congress of Radiology 2009 (ECR SF1B).

“MR is a powerful method for imaging the prostate gland because its high spatial resolution provides excellent soft-tissue contrast, which may aid the detection and localization of malignant lesions, the evaluation of disease stage based on the extraprostatic extension of cancer, and the detection of local or distant disease recurrence after treatment,” said Jurgen J. Ftterer, MD, PhD, of the department of radiology at Radboud University Nijmegen Medical Centre in the Netherlands.

What 3T MRI adds
The signal-to-noise ratio increases almost linearly with magnetic field strength, whereas the noise remains nearly unchanged with 3T MRI. Thus, the SNR is approximately two times higher at 3T compared with 1.5T. The most significant benefit of this difference is the increase of spatial resolution, which improves the depiction of anatomical details and/or shortens acquisition time, thereby increasing patient throughput, Dr. Ftterer explained.

The chemical shift effect also increases linearly with magnetic field strength. Spectral resolution at 3T is therefore enhanced compared with 1.5T. Signal intensity and frequency dispersion are higher, which may lead to better tumor characterization. In dynamic contrast-enhanced MR imaging, the increase in SNR can be used to improve the temporal resolution of dynamic measurements. Increased temporal resolution may improve the accuracy of measurement of pharmacokinetic parameters.

Endorectal 3T T2-weighted and high spatial resolution dynamic contrast-enhanced MRI are able to identify morphological and vascular details, which may guide not only the detection and staging of disease but the direction of biopsies and treatment.

Signal intensity changes obtained during dynamic image acquisition provide an estimate of the amount of contrast material that has accumulated in lesions.

The passage of contrast into and out of lesions reflects the kinetic properties of tissue physiology, such as Ktrans and Ve values, and provides an indication of microvascular permeability and angiogenetic potential, according to B. Nicolas Bloch, MD, who discussed MR perfusion and high-resolution imaging. Dr. Bloch is an instructor in radiology at Beth Israel Deaconess Medical Center in Boston.

The high field strength of 3T MRI is particularly useful in dynamic contrast-enhanced studies of the prostate gland. “Dynamic contrast-enhanced MRI makes it possible to combine fast imaging-less than three seconds per image set-with good spatial resolution. This technique directly benefits from the increased SNR at 3T,” Dr. Ftterer said.

Drawbacks
High-field MRI has its drawbacks and challenges, however, including a quadrupling of radiofrequency power deposition compared with 1.5T, shorter T2- and longer T1-relaxation times, increased susceptibility differences, dielectric effect, and signal heterogeneity from larger B1 field variations. Using thinner slices and increasing the spatial resolution or bandwidth at a higher field may partially circumvent some of these issues, but these changes will offset some of the SNR increase gained with 3T imaging.

In addition, the loss in SNR is less than linear with voxel size due to the decreasing line width (e.g., when resolution is increased from 0.075 to 0.094 cm3, the SNR decreases between 44% and 60%). Due to radiofrequency penetration effects, it can be difficult to achieve good RF field homogeneity. Parallel imaging techniques, increased TR, reduced flip angle, and increased RF pulse duration can be used to overcome these problems, but at the expense of SNR.

Despite these difficulties, the increase in SNR provided by 3T MRI is likely to expand the potential clinical applications for evaluating the prostate, Dr. Ftterer said.

“Endorectal 1.5T MRI is a common method of evaluating men with suspected prostate cancer. But in the next few years, 3T MRI will become the standard. An SNR at 3T that is equal to the SNR at 1.5T with an endorectal coil is a big advantage,” he said.

 

Related Videos
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Related Content